Robert Millman, formerly the chief IP counsel for Alnylam Pharmaceuticals, has joined healthcare venture capital firm MPM Capital as an executive partner.
Before Alnylam, Millman served as patent counsel at Millennium Pharmaceuticals.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.